ライフサイエンスコーパス: hemodialysis

1 tion rate, <15 mL/min/1.73 m(2) or requiring hemodialysis).

2 in this cohort of patients with diabetes on hemodialysis.

3 t patient adherence and self-management with hemodialysis.

4 ce of clot density on outcome in patients on hemodialysis.

5 in patients with hyperphosphatemia receiving hemodialysis.

6 a very low probability of harm with frequent hemodialysis.

7 atients participating in a trial of frequent hemodialysis.

8 in patients with hyperphosphatemia receiving hemodialysis.

9 raditional risk factors in patients starting hemodialysis.

10 20 patients (28%) randomized to conventional hemodialysis.

11 o normalize exercise capacity in patients on hemodialysis.

12 may contribute to BPA burden in patients on hemodialysis.

13 valuating the aortic geometry in patients on hemodialysis.

14 rmacokinetics at steady state in patients on hemodialysis.

15 PD is now equivalent to that with in-center hemodialysis.

16 few studies have examined RKF in patients on hemodialysis.

17 gradients in 73 controls and 156 patients on hemodialysis.

18 on to oxygen transport exists in patients on hemodialysis.

19 -blockers among patients receiving long-term hemodialysis.

20 der visits for patients with ESRD undergoing hemodialysis.

21 osis affecting patients undergoing long-term hemodialysis.

22 in chronic kidney disease patients receiving hemodialysis.

23 n or graft placement in the first 90 days of hemodialysis.

24 iate need for extracorporeal life support or hemodialysis.

25 and protectorates in which residents receive hemodialysis.

26 e of an arteriovenous fistula (AVF) at first hemodialysis.

27 support the concept of dysfunctional HDL in hemodialysis.

28 receiving maintenance in-center (outpatient) hemodialysis.

29 Fractures are frequent in patients receiving hemodialysis.

30 The second patient received hemodialysis.

31 red with other modalities when used at first hemodialysis.

32 ptimal in the majority of patients receiving hemodialysis.

33 vival using three strategies for patients on hemodialysis.

34 Two children required hemodialysis.

35 oo hemodynamically unstable for intermittent hemodialysis.

36 e (PTH) concentrations in patients receiving hemodialysis.

37 pressor circulatory support and intermittent hemodialysis.

38 ated to potassium homeostasis in patients on hemodialysis.

39 rtality in patients with ESRD on maintenance hemodialysis.

40 t of arteriovenous synthetic grafts used for hemodialysis.

41 Both neutralizing (hemodialysis, 1.26 IU/ml, versus postsurgical, 0.95; P <

42 ersus postsurgical, 0.95; P < 0.05) and IgG (hemodialysis, 1.94 IU/ml, versus postsurgical, 1.27; P <

43 at extracorporeal treatment sessions may use hemodialysis (1D) or continuous renal replacement therap

44 rs on BPA levels in 69 prevalent patients on hemodialysis: 28 patients started on polysulfone dialyze

45 n rate per 5-U increments (0.93; 0.91-0.95), hemodialysis (3.25; 2.42-4.37), New York Heart Associati

46 All 8 patients were treated with hemodialysis, 7 of 8 patients were treated with bowel de

47 Thus, in patients on hemodialysis, a denser clot structure may be a potent in

48 cardiovascular events in patients receiving hemodialysis, a full-scale trial is needed to assess pot

49 UTs) are difficult to remove by conventional hemodialysis; a high degree of protein binding reduces t

50 nous elastic recoil after PTA of stenoses in hemodialysis access circuits is common, but its occurren

51 re-matching techniques were used to evaluate hemodialysis access rates between patients of different

52 cost-effective, intervention for increasing hemodialysis adherence in high-risk patients, especially

53 In patients on hemodialysis, age did not associate with increased ascen

54 As with hemodialysis, almost half of all deaths on PD occur beca

55 Hemodialysis, although beneficial in terms of uremic tox

56 cteremia (SAB), and clinical outcomes in 100 hemodialysis and 100 postsurgical SAB patients.

57 f CKD (baseline hemoglobin 9.5-12.0 g/dl) on hemodialysis and being treated with stable doses of reco

58 alysis in a cohort of patients not receiving hemodialysis and found no significant association betwee

59 detected in 19 patients (25%): one required hemodialysis and four underwent renal transplant.

60 ecal metabolite profiles between patients on hemodialysis and household contacts on the same diet, wh

61 ng patients with ESRD undergoing maintenance hemodialysis and is a significant contributor to health

62 Hemodialysis and peritoneal dialysis were the only forms

63 ed to supratherapeutic levels in patients on hemodialysis and should be avoided.

64 rm outcomes of patients who undergo incident hemodialysis and subsequently develop retinal vascular o

65 d patient improved immediately upon starting hemodialysis and was extubated within 48 hours and disch

66 rease may reflect cellular stress induced by hemodialysis and/or strong intracellular phosphate regul

67 equirement for vasopressors, requirement for hemodialysis, and nontrauma admission.

68 tatus (KPS 10%-40%), living donor LT, pre-LT hemodialysis, and the donor risk index (all P < .001).

69 lysis independence rates at 6 and 12 months, hemodialysis- and chemotherapy-related adverse events, a

70 Patients needing hemodialysis are advised to have arteriovenous fistulas

71 ced practitioner within the first 90 days of hemodialysis are more likely to undergo surgery to creat

72 yperplasia development in a porcine model of hemodialysis arteriovenous graft stenosis.

73 pitalized (16.8% vs. 21.7%, P = 0.03), or on hemodialysis at time of transplant (2.6% vs. 8.2%, P < 0

74 nd matched for age, sex, and the duration of hemodialysis (at a 1:5 ratio) with patients without ocul

75 mal hyperplasia (VNH) at the outflow vein of hemodialysis AVF is a major factor contributing to failu

76 an important health concern for patients on hemodialysis because of their immunosuppressed state and

77 y of patients aged >/=18 years who initiated hemodialysis between 2004 and 2012 at five Canadian dial

78 se in the US Renal Data System who initiated hemodialysis between January 1, 2006, and December 31, 2

79 termine the efficacy of treatment, including hemodialysis, bowel decontamination, antibiotics, and th

80 ased risk of mortality in patients receiving hemodialysis, but high values are a marker for poor nutr

81 istula (AVF) or arteriovenous graft (AVG) vs hemodialysis catheter (HC), the National Kidney Foundati

82 surrounding the distal tip of her indwelling hemodialysis catheter.

83 AVF, arteriovenous graft, and intravascular hemodialysis catheter.

84 ted through Washington University-affiliated hemodialysis centers involving ESRD patients with poor a

85 chemotherapy regimen, the use of high-cutoff hemodialysis compared with conventional hemodialysis did

86 Twenty-seven patients on hemodialysis completed a crossover study consisting of t

87 Given the increasing number of elderly hemodialysis-dependent patients with concomitant chronic

88 The third patient was initially started on hemodialysis despite high norepinephrine requirements an

89 Patients treated with hemodialysis develop severely reduced functional capacit

90 yme is proposed, by refitting a conventional hemodialysis device bearing a dialyzer, two pumps and co

91 toff hemodialysis compared with conventional hemodialysis did not result in a statistically significa

92 of 125 patients (16%) randomized to frequent hemodialysis died during the combined trial and post-tri

93 trate anticoagulation-continuous veno-venous hemodialysis during a 3-year period (n = 1,070) were inc

94 nsplantation; and 1 patient required further hemodialysis during follow-up.

95 All patients received continuous veno-venous hemodialysis during the LT.

96 nd we identified 105,956 patients undergoing hemodialysis during the period from January 1997 to Dece

97 Intensive hemodialysis (eight 5-hour sessions over 10 days) with e

98 ospective cohort of 571 patients on incident hemodialysis enrolled in the Predictors of Arrhythmic an

99 loramines in the water prior to entering the hemodialysis equipment is essential.

100 The capacity of the hemodialysis equipment to clear chloramine can vary as a

101 Patients with CKD on hemodialysis exhibit increased cardiovascular risk.

102 Patients on hemodialysis exhibited a pattern of ischemic brain injur

103 made of purified fibrinogen from patients on hemodialysis exhibited significantly thinner fibers comp

104 e AVF measurements, patients enrolled in the Hemodialysis Fistula Maturation Study underwent up to fi

105 fibrosis greater than 30% or for patients on hemodialysis for 2 months or longer.

106 group vs 33.3% (n = 16) in the conventional hemodialysis group (between-group difference, 8.0% [95%

107 months was 41.3% (n = 19) in the high-cutoff hemodialysis group vs 33.3% (n = 16) in the conventional

108 ed adverse events was 43% in the high-cutoff hemodialysis group vs 39% in the conventional hemodialys

109 emodialysis group vs 39% in the conventional hemodialysis group; chemotherapy-related serious adverse

110 ved a cohort of 115,425 patients on incident hemodialysis >/=67 years old from the US Renal Data Syst

111 ip between BP and downstream ischemia during hemodialysis has not been characterized.

112 Interventional studies in hemodialysis have been limited and inconsistent in their

113 gs suggest that women undergoing maintenance hemodialysis have substantially higher risks for hospita

114 have indicated that patients on maintenance hemodialysis have worse survival compared with kidney tr

115 ndergoing either peritoneal dialysis (PD) or hemodialysis (HD) have assessed the association of uncor

116 of HDL functionality in patients undergoing hemodialysis (HD) or peritoneal dialysis (PD) with those

117 anemic (Hb</=10.0 g/dl) patients incident to hemodialysis (HD) or peritoneal dialysis (PD).

118 bolic syndrome (MetS) (n = 13), and diabetic hemodialysis (HD) patients (n = 24).

119 Cardiovascular disease among hemodialysis (HD) patients is linked to poor outcomes.

120 In incident hemodialysis (HD) patients, the use of catheters is asso

121 adoxically associated with better outcome in hemodialysis (HD) patients.

122 Hemodynamic stress during hemodialysis (HD) results in recurrent segmental ischemi

123 evidence of survival benefit when initiating hemodialysis (HD) via arteriovenous fistula (AVF) or art

124 ry artery calcification (CAC) in patients on hemodialysis (HD).

125 a (AVF) is the preferred vascular access for hemodialysis (HD).

126 The Hemodialysis (HEMO) Study showed that high-dose hemodial

127 alternative dialysis modalities such as home hemodialysis (HHD) with KTx recipients.

128 efficiently removed from the circulation by hemodialysis ("high dialyzability") whereas others are n

129 h comprises peritoneal dialysis (PD) or home hemodialysis (home HD), offers patients with ESRD greate

130 ) maturation prevent optimal fistula use for hemodialysis; however, the mechanism of venous remodelin

131 on is a serious and frequent complication of hemodialysis; however, there is no evidence-based consen

132 (HR = 9.46; 95% CI: 3.98-22.47; P < 0.0001), hemodialysis (HR = 27.44; 95% CI: 12.63-59.61; P < 0.000

133 mong 111,653 patients undergoing maintenance hemodialysis in facilities operated by a large dialysis

134 ed 35,959 patients aged >/=67 years starting hemodialysis in the United States from a national regist

135 Of the 464,547 patients beginning hemodialysis in this cohort, first hemodialysis with an

136 in a statistically significant difference in hemodialysis independence at 3 months.

137 Primary end point was hemodialysis independence at 3 months; secondary end poi

138 To compare the hemodialysis independence rate among patients newly diag

139 The hemodialysis independence rate at 3 months was 41.3% (n

140 ependence at 3 months; secondary end points: hemodialysis independence rates at 6 and 12 months, hemo

141 Median duration between hemodialysis initiation and subsequent CUA development w

142 Greater CLurea rate 1 year after hemodialysis initiation associated with better survival.

143 tigated whether baseline factors recorded at hemodialysis initiation would identify patients at risk

144 e (CLurea) data at baseline and 1 year after hemodialysis initiation, we examined the association of

145 was constructed to reflect progression from hemodialysis initiation.

146 In conclusion, a 12-month frequent in-center hemodialysis intervention significantly reduced long-ter

147 m effects of the 12-month frequent in-center hemodialysis intervention.

148 lasma LDL from 90 uremia patients undergoing hemodialysis into 5 subfractions (L1-L5) according to ch

149 Hemodialysis is associated with significant circulatory

150 he role of extracorporeal treatments such as hemodialysis is poorly defined at present.

151 Intermittent hemodialysis is preferred initially (1D), but continuous

152 The single leading cause of mortality on hemodialysis is sudden cardiac death.

153 the main source of phosphate removed during hemodialysis is the intracellular compartment.

154 Intermittent hemodialysis is the modality of choice and continuous mo

155 l replacement therapies may be considered if hemodialysis is unavailable (2D).

156 The optimal BP target for patients receiving hemodialysis is unknown.

157 ong-term mortality, suggesting that frequent hemodialysis may benefit selected patients with ESRD.

158 ger-term heparin reexposure (eg, for chronic hemodialysis) may also be reasonable.

159 rospective cohort of 171 patients on chronic hemodialysis (mean+/-SD age =59+/-11 years old; 54% men)

160 The use of high-cutoff hemodialysis membranes in combination with antimyeloma t

161 d-stage renal disease undergoing maintenance hemodialysis (MHD) are highly prone to infections.

162 ts (DERs) of patients undergoing maintenance hemodialysis (MHD) have shown mixed results.

163 In maintenance hemodialysis (MHD) patients, low protein intake is assoc

164 The Frequent Hemodialysis Network Daily Trial randomized 245 patients

165 antation, chronic renal replacement therapy (hemodialysis or peritoneal dialysis), and missing peak p

166 gan failure (OR, 1.24 [CI, 1.08 to 1.41]) or hemodialysis (OR, 1.61 [CI, 1.12 to 2.17]), and social d

167 No patients undergoing peritoneal dialysis, hemodialysis, or nondialysis who experienced renal failu

168 patient was a nursing home resident, was on hemodialysis, or was readmitted within 30 days of a prio

169 ort of 6538 patients who started maintenance hemodialysis over a 4-year period (January 2007 through

170 (1) versus 6.1% (7) required postprocedural hemodialysis (P<0.05).

171 In prevalent patients on hemodialysis, PAD (ABix<0.9 or >1.4/incompressible) was

172 A long-term hemodialysis patient was exposed to gadolinium several t

173 oxide (TMAO) with cardiovascular outcomes in hemodialysis patients and assessed whether this associat

174 ore, we studied fecal metabolite profiles of hemodialysis patients and healthy controls using a gas c

175 etected at significantly different levels in hemodialysis patients and healthy controls.

176 Hemodialysis patients are high absorbers of intestinal c

177 period-prevalent sample of 7384 maintenance hemodialysis patients at 132 facilities from the Dialysi

178 ion associates with cardiovascular events in hemodialysis patients but the effects differ by race.

179 us and cardiac hospitalizations and death in hemodialysis patients have not been reported.

180 L5% was higher in hemodialysis patients in whom ischemic lower-extremity P

181 red (3.03% [IQR, 2.36-4.54], n = 22) than in hemodialysis patients in whom PAD did not occur (1.13% [

182 associated with arteriovenous fistula use in hemodialysis patients is due to the avoidance of cathete

183 irst record of dabigatran prescription among hemodialysis patients occurred 45 days after the drug be

184 Transplant Recipients, we identified 15 125 hemodialysis patients who underwent first deceased trans

185 f dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation.

186 From 1/2012 to 8/2015, 232 chronic hemodialysis patients with central venous catheters as v

187 f HDL cholesterol on outcomes in maintenance hemodialysis patients with diabetes.

188 Hemodialysis patients with newly diagnosed CUA (n=1030)

189 lacebo-controlled trial that randomized 3883 hemodialysis patients with secondary hyperparathyroidism

190 ched by age, sex, and race in a 1:2 ratio to hemodialysis patients without CUA (n=2060).

191 sons with end-stage renal disease (including hemodialysis patients), blood and tissue donors, persons

192 disease, end-stage renal disease (including hemodialysis patients), or HIV infection; travelers to H

193 rise in iron utilization, particularly among hemodialysis patients, and an unprecedented increase in

194 ver, it may not be the best approach for all hemodialysis patients, because likelihood of successful

195 to increase coronary artery disease risk in hemodialysis patients, but its effect on the risk of per

196 ccurrence of ischemic lower-extremity PAD in hemodialysis patients.

197 tion with all-cause mortality among incident hemodialysis patients.

198 fts and helps maintain cognitive function in hemodialysis patients.

199 al metabolism may affect outcomes in chronic hemodialysis patients.

200 g vaccine effectiveness in a cohort of adult hemodialysis patients.

201 torvastatin to reduce cardiovascular risk in hemodialysis patients.

202 it is related to cardiovascular survival in hemodialysis patients.

203 fectiveness to reduce cardiovascular risk in hemodialysis patients.

204 linked to thrombotic events and mortality in hemodialysis patients.

205 ions, ScvO2 has received little attention in hemodialysis patients.

206 ic lower-extremity PAD developed in 24.4% of hemodialysis patients.

207 of patients with end-stage renal disease on hemodialysis, PCI was associated with significantly high

208 ), and 94 (75%) countries had facilities for hemodialysis, peritoneal dialysis, and kidney transplant

209 (34%) countries in Africa had facilities for hemodialysis, peritoneal dialysis, and kidney transplant

210 Hemodialysis, peritoneal dialysis, and transplantation s

211 high rate of cardiovascular mortality in the hemodialysis population, clinicians are obligated to exp

212 P < 0.05) antibody levels were higher in the hemodialysis population.

213 rmining latent tuberculosis infection in the hemodialysis population.

214 rmining latent tuberculosis infection in the hemodialysis population.

215 One of the fundamental goals of the hemodialysis prescription is to maintain serum potassium

216 with end-stage renal disease on maintenance hemodialysis presented to the emergency room with abdomi

217 odialysis (HEMO) Study showed that high-dose hemodialysis providing a single-pool Kt/Vurea of 1.71 pr

218 The incidence of hemodialysis-related adverse events was 43% in the high-

219 ator liberation, and acute kidney injury +/- hemodialysis requirement.

220 e likely to have a history of renal failure, hemodialysis, residence in a long-term-care facility, lo

221 Apixaban 2.5 mg twice daily in patients on hemodialysis resulted in drug exposure comparable with t

222 Our data suggest that hemodialysis results in significant brain injury and tha

223 uster-randomized, pragmatic trial evaluating hemodialysis session duration, to illustrate challenges

224 de (n = 503) or placebo (n = 513) after each hemodialysis session for 26 weeks.

225 Mean BPA levels increased after one hemodialysis session with polysulfone dialyzers but not

226 ganic phosphate (Pi) removed during a 4-hour hemodialysis session, a maximum of 10% may be extracted

227 ephrectomized pigs each underwent one 3-hour hemodialysis session, during which the extracorporeal ci

228 In all, 23.5% of hemodialysis sessions featured cerebral ischemia; 31.9%

229 s prospectively gathered from 635 real-world hemodialysis sessions in 58 prevalent patients.

230 It allows prolonged hemodialysis sessions in critically ill patients without

231 (frequent) or three (conventional) in-center hemodialysis sessions per week for 12 months.

232 on recombinant human erythropoietin for the hemodialysis study) for 4 weeks, with a 2-week follow-up

233 e doses of recombinant human erythropoietin (hemodialysis study).

234 otal of 1232 white and black patients of the Hemodialysis Study, and analyzed the association of TMAO

235 nant human erythropoietin control arm in the hemodialysis study, and without clinically significant e

236 In the hemodialysis study, treatment with GSK1278863 in the 5-m

237 is less well defined for patients receiving hemodialysis than for those receiving peritoneal dialysi

238 dy drug was administered 3 times weekly with hemodialysis; the oral study drug was administered daily

239 We randomized 126 hypertensive patients on hemodialysis to a standardized predialysis systolic BP o

240 sy-proven myeloma cast nephropathy requiring hemodialysis treated at 48 French centers between July 2

241 dney disease stage 5 undergoing intermittent hemodialysis treatment (CKD 5D) and 8 kidney transplant

242 sis day, patients with ESRD on thrice-weekly hemodialysis underwent overnight polysomnography along w

243 Chronic hemodialysis use was more common among patients with MRS

244 d with myeloma cast nephropathy treated with hemodialysis using a high-cutoff dialyzer (with very lar

245 to increase the odds of a patient beginning hemodialysis using an AVF by 11-fold (odds ratio, 11.42

246 of clinical fractures in patients receiving hemodialysis using data from the Evaluation of Cinacalce

247 inogen from healthy controls and patients on hemodialysis using the calcium-dependent IF-1 mAb agains

248 me symptoms, and cerebral oxygenation during hemodialysis, using continuous BP and cerebral oxygenati

249 Hemodialysis vascular access recommendations promote art

250 care requires an individualized approach to hemodialysis vascular access, on the basis of each patie

251 nce regarding the role of indoxyl sulfate in hemodialysis vascular access.

252 Hemodialysis vascular accesses are prone to recurrent st

253 dress to maximize the benefits of initiating hemodialysis via fistula in patients with end-stage rena

254 wer tertiles of ScvO2 were older, had longer hemodialysis vintage, lower systolic blood pressure, low

255 ad high C-reactive protein levels and longer hemodialysis vintage.

256 lity hazard for frequent versus conventional hemodialysis was 0.54 (95% confidence interval, 0.31 to

257 onal visit per month in the first 90 days of hemodialysis was associated with a 21% increase in the o

258 l modifications, fibrinogen from patients on hemodialysis was glycosylated and guanidinylated.

259 For 65 prevalent nondiabetic patients on hemodialysis, we measured ankle-brachial pressure index

260 rocedural systemic vasodilator infusion, and hemodialysis were independently associated with an incre

261 experienced delayed graft function requiring hemodialysis which was discontinued on postoperative day

262 latent tuberculosis infection in patients on hemodialysis while offering a comparable level of specif

263 47 patients with type 2 diabetes mellitus on hemodialysis who participated in the German Diabetes Dia

264 risk of mortality among patients undergoing hemodialysis who subsequently developed retinal artery o

265 increased among patients undergoing incident hemodialysis who subsequently developed retinal vascular

266 ult patients receiving maintenance in-center hemodialysis who were discharged between January 1, 2003

267 ive HCV genotype 1a male post-LT patients on hemodialysis who were treated with EBR/GZR with or witho

268 Individuals on hemodialysis, who have an unexplained increase in athero

269 of patients receiving maintenance in-center hemodialysis will be readmitted or visit an emergency ro

270 However, the group initiating hemodialysis with a catheter after failed fistula placem

271 nts in the United States frequently initiate hemodialysis with a central venous catheter (CVC) and su

272 We identified 479 patients starting hemodialysis with a CVC at a large medical center (durin

273 In conclusion, among patients initiating hemodialysis with a CVC, the annual cost of access-relat

274 lan-Meier analysis revealed that patients on hemodialysis with a denser clot structure had increased

275 ed mortality outcomes in patients initiating hemodialysis with a fistula placed first, a catheter aft

276 ack patients and Hispanic patients initiated hemodialysis with an AVF less frequently despite being y

277 79-0.84] for insured) persistently initiated hemodialysis with an AVF less frequently than white pati

278 ients and Hispanic patients tend to initiate hemodialysis with an AVF less frequently than white pati

279 beginning hemodialysis in this cohort, first hemodialysis with an AVF ranged from 11.1% to 22.2% depe

280 ,075 patients, more white patients initiated hemodialysis with an AVF than black patients or Hispanic

281 should be considered in patients undergoing hemodialysis with atrial fibrillation (AF) remains contr

282 Our study included 20 patients receiving hemodialysis with calciphylaxis (cases) and 20 patients

283 Among patients receiving hemodialysis with moderate to severe secondary hyperpara

284 Among patients receiving hemodialysis with moderate to severe secondary hyperpara

285 ls were conducted in 1023 patients receiving hemodialysis with moderate to severe secondary hyperpara

286 only modestly higher in patients undergoing hemodialysis with new-onset AF than in those without AF,

287 sk of ischemic stroke in patients undergoing hemodialysis with new-onset AF, in comparison with those

288 Database during 1998 to 2011 for patients on hemodialysis with new-onset nonvalvular AF and matched s

289 ellular BPA in PBMCs increased after chronic hemodialysis with polysulfone dialyzers (from 0.039+/-0.

290 Furthermore, chronic hemodialysis with polysulfone dialyzers increased oxidat

291 e accumulation during continuous veno-venous hemodialysis with regional citrate anticoagulation by in

292 ate binders/vitamin D) in patients receiving hemodialysis with secondary hyperparathyroidism (intact

293 and other secondary outcomes in patients on hemodialysis with serum 25(OH)D <30 ng/ml.

294 lcet vs IV placebo in 683 patients receiving hemodialysis with serum parathyroid hormone (PTH) concen

295 with a fistula placed first, 9794 initiated hemodialysis with that fistula, and 8230 initiated dialy

296 ncreased serum 25(OH)D levels in patients on hemodialysis with vitamin D insufficiency or deficiency,

297 utility of clusterin for prediction of DGF (hemodialysis within 7 days of transplantation) was compa

298 ciphylaxis (cases) and 20 patients receiving hemodialysis without calciphylaxis (controls) matched fo

299 occlusion compared with patients undergoing hemodialysis without ocular disorders.

300 As reported previously, frequent in-center hemodialysis yielded favorable effects on the coprimary